Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Increased prevalence of nonalcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD) has been reported. However, the effects of NAFLD on the outcome of IBD remains unclear. We investigated whether the presence of NAFLD could influence the outcomes of patients with IBD. Methods: We recruited 3,356 eligible patients with IBD into our study between November 2005 and November 2020. Hepatic steatosis and fibrosis were diagnosed using hepatic steatosis index of ≥30 and fibrosis-4 of ≥1.45, respectively. The primary outcome was clinical relapse, defined based on the following: IBD-related admission, surgery, or first use of corticosteroids, immunomodulators, or biologic agents for IBD. Results: The prevalence of NAFLD in patients with IBD was 16.7%. Patients with hepatic steatosis and advanced fibrosis were older, had a higher body mass index, and were more likely to have diabetes (all p<0.05). Conclusions: Hepatic steatosis was independently associated with increased risks of clinical relapse in patients with ulcerative colitis and Crohn’s disease, whereas fibrotic burden in the liver was not. Future studies should investigate whether assessment and therapeutic intervention for NAFLD will improve the clinical outcomes of patients with IBD.
Abstract
Background/Aims: Increased prevalence of nonalcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD) has been reported. However, the effects of NAFLD on the outcome of IBD remains unclear. We investigated whether the presence of NAFLD could influence the outcomes of patients with IBD. Methods: We recruited 3,356 eligible patients with IBD into our study between November 2005 and November 2020. Hepatic steatosis and fibrosis were diagnosed using hepatic steatosis index of ≥30 and fibrosis-4 of ≥1.45, respectively. The primary outcome was clinical relapse, defined based on the following: IBD-related admission, surgery, or first use of corticosteroids, immunomodulators, or biologic agents for IBD. Results: The prevalence of NAFLD in patients with IBD was 16.7%. Patients with hepatic steatosis and advanced fibrosis were older, had a higher body mass index, and were more likely to have diabetes (all p<0.05). Conclusions: Hepatic steatosis was independently associated with increased risks of clinical relapse in patients with ulcerative colitis and Crohn’s disease, whereas fibrotic burden in the liver was not. Future studies should investigate whether assessment and therapeutic intervention for NAFLD will improve the clinical outcomes of patients with IBD.
참고문헌 (43)
- Chang J, "Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing", Gastroenterology, 153, pp.723~731 (2017)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Associazione Italiana per lo Studio del Fegato(AISF), "Non-alcoholic fatty liver disease in adults 2021 : a clinical practice guideline of the Italian Association for the Study of the Liver(AISF), the Italian Society of Diabetology(SID)and the Italian Society of Obesity(SIO)", Dig Liver Dis, 54, pp.170~182 (2022)
- Parthasarathy G, "Pathogenesis of nonalcoholic steatohepatitis : an overview", Hepatol Commun, 4, pp.478~492 (2020)
- Leung C, "The role of the gut microbiota in NAFLD", Nat Rev Gastroenterol Hepatol, 13, pp.412~425 (2016)
- Aron-Wisnewsky J, "Gut microbiota and human NAFLD : disentangling microbial signatures from metabolic disorders", Nat Rev Gastroenterol Hepatol, 17, pp.279~297 (2020)
- Weingarden AR, "Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease", Gut Microbes, 8, pp.238~252 (2017)
- Lin A, "Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease : a systematic review and metaanalysis", Inflamm Bowel Dis, 27, pp.947~955 (2021)
- Seo JW, "Non-cirrhotic portal hypertension related to azathioprine therapy in a patient with Crohn’s disease", Intest Res, 19, pp.247~251 (2021)
- Glassner K, "Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease", Inflamm Bowel Dis, 23, pp.998~1003 (2017)
- European Association for the Study of the Liver(EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", Obes Facts, 9, pp.65~90 (2016)
- Torres J, "Crohn’s disease", Lancet, 389, pp.1741~1755 (2017)
- Ungaro R, "Ulcerative colitis", Lancet, 389, pp.1756~1770 (2017)
- Lamb CA, "British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults", Gut, 68(Suppl 3), pp.s1~s106 (2019)
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Choi CH, "Second Korean guideline for the management of ulcerative colitis", Korean J Gastroenterol, 69, pp.1~28 (2017)
- Park JJ, "Second Korean guidelines for the management of Crohn’s disease", Intest Res, 15, pp.38~67 (2017)
- Hisamatsu T, "Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis : a subpopulation analysis of global phase 3 induction and maintenance studies(UNIFI)", Intest Res, 19, pp.386~397 (2021)
- Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281 (2019)
- Kang SH, "KASL clinical practice guidelines : management of nonalcoholic fatty liver disease", Clin Mol Hepatol, 27, pp.363~401 (2021)
- Chang JW, "Hepatic steatosis index in the detection of fatty liver in patients with chronic hepatitis b receiving antiviral therapy", Gut Liver, 15, pp.117~127 (2021)
- Mendall MA, "Body mass index in young men and risk of inflammatory bowel disease through adult life : a population-based Danish cohort study", Sci Rep, 9, pp.6360~ (2019)
- Weng MT, "Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease", Intest Res, 20, pp.224~230 (2022)
- Petroff D, "Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes : an individual patient data meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.185~198 (2021)
- Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection : comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Lee CH, "The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease", Intest Res, 18, pp.79~84 (2020)
- Noorian S, "The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases : nationwide analysis", Inflamm Bowel Dis, 28, pp.878~887 (2022)
- Adamina M, "ECCO guidelines on therapeutics in Crohn’s disease : surgical treatment", J Crohns Colitis, 14, pp.155~168 (2020)
- Barrett K, "Using corticosteroids appropriately in inflammatory bowel disease : a guide for primary care", Br J Gen Pract, 68, pp.497~498 (2018)
- Zou ZY, "Systematic review with metaanalysis : epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease", Inflamm Bowel Dis, 25, pp.1764~1772 (2019)
- Bargiggia S, "Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease : study of 511 subjects at a single center", J Clin Gastroenterol, 36, pp.417~420 (2003)
- NCD Risk Factor Collaboration(NCD-RisC), "Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016 : a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults", Lancet, 390, pp.2627~2642 (2017)
- du Plessis J, "Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD", PLoS One, 11, pp.e0166048~ (2016)
- Yki-Järvinen H, "Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome", Lancet Diabetes Endocrinol, 2, pp.901~910 (2014)
- Canfora EE, "Gut microbial metabolites in obesity, NAFLD and T2DM", Nat Rev Endocrinol, 15, pp.261~273 (2019)
- Delli Bovi AP, "Oxidative stress in non-alcoholic fatty liver disease : an updated mini review", Front Med(Lausanne), 8, pp.595371~ (2021)
- Farrell GC, "NAFLD in Asia : as common and important as in the West", Nat Rev Gastroenterol Hepatol, 10, pp.307~318 (2013)
- Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
- Tacke F, "Non-alcoholic fatty liver disease(NAFLD)", non-alcoholic steatohepatitis(NASH)-related liver fibrosis : mechanisms, treatment and prevention, 2021, pp.9, 729~
- Rea IM, "Age and age-related diseases : role of inflammation triggers and cytokines", Front Immunol, 9, pp.586~ (2018)
- Wang H, "Immunological mechanisms and therapeutic targets of fatty liver diseases", Cell Mol Immunol, 18, pp.73~91 (2021)
- Anstee QM, "From NASH to HCC : current concepts and future challenges", Nat Rev Gastroenterol Hepatol, 16, pp.411~428 (2019)